173 related articles for article (PubMed ID: 21355379)
1. Certolizumab pegol and rheumatoid arthritis. Just another TNF alpha antagonist, no therapeutic advantage.
Prescrire Int; 2010 Dec; 19(111):279. PubMed ID: 21355379
[TBL] [Abstract][Full Text] [Related]
2. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.
Ramiro S; van Tubergen AM; Landewé RB
Expert Rev Clin Immunol; 2010 Sep; 6(5):713-20. PubMed ID: 20828279
[TBL] [Abstract][Full Text] [Related]
3. How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients.
Aletaha D
BioDrugs; 2014 Apr; 28 Suppl 1():S3-4. PubMed ID: 24687233
[No Abstract] [Full Text] [Related]
4. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
5. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
Pasut G
BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
Punzi L; Lapadula G; Mathieu A
BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
8. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
Lazebnik LB; Kniazev OV
Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233
[No Abstract] [Full Text] [Related]
9. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis.
Med Lett Drugs Ther; 2014 Feb; 56(1435):10-2. PubMed ID: 24662976
[No Abstract] [Full Text] [Related]
11. Drug safety evaluation of certolizumab pegol.
Ferrante M; Vermeire S; Rutgeerts PJ
Expert Opin Drug Saf; 2014 Feb; 13(2):255-66. PubMed ID: 24156537
[TBL] [Abstract][Full Text] [Related]
12. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
Meroni PL; Valesini G
BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
[TBL] [Abstract][Full Text] [Related]
13. Biologic agents in rheumatology: act II.
Kavanaugh A
Clin Exp Rheumatol; 2010; 28(3 Suppl 59):S2-4. PubMed ID: 20576218
[No Abstract] [Full Text] [Related]
14. Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis.
Tlucek PS; Stone DU
Cornea; 2012 Jan; 31(1):90-1. PubMed ID: 21941174
[TBL] [Abstract][Full Text] [Related]
15. The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis.
Fleischmann R
Expert Opin Biol Ther; 2010 May; 10(5):773-86. PubMed ID: 20230188
[TBL] [Abstract][Full Text] [Related]
16. [Certolizumab pegol].
Delgado Frías E; Díaz González JF
Reumatol Clin; 2011 Mar; 6S3():S7-11. PubMed ID: 21794764
[TBL] [Abstract][Full Text] [Related]
17. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.
Palframan R; Airey M; Moore A; Vugler A; Nesbitt A
J Immunol Methods; 2009 Aug; 348(1-2):36-41. PubMed ID: 19567252
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
19. Certolizumab pegol.
Melmed GY; Targan SR; Yasothan U; Hanicq D; Kirkpatrick P
Nat Rev Drug Discov; 2008 Aug; 7(8):641-2. PubMed ID: 18670430
[TBL] [Abstract][Full Text] [Related]
20. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
